Literature DB >> 24324035

Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort.

David A Calhoun1, John N Booth, Suzanne Oparil, Marguerite R Irvin, Daichi Shimbo, Daniel T Lackland, George Howard, Monika M Safford, Paul Muntner.   

Abstract

Refractory hypertension is an extreme phenotype of antihypertensive treatment failure. Participants in the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study, a large (n=30 239), population-based cohort were evaluated to determine the prevalence of refractory hypertension and associated cardiovascular risk factors and comorbidities. Refractory hypertension was defined as uncontrolled blood pressure (systolic/diastolic, ≥140/90 mm Hg) on ≥5 antihypertensive drug classes. Participants with resistant hypertension (systolic/diastolic, ≥140/90 mm Hg on ≥3 or <140/90 mm Hg on ≥4 antihypertensive classes) and all participants treated for hypertension served as comparator groups. Of 14 809 REGARDS participants receiving antihypertensive treatment, 78 (0.5%) had refractory hypertension. The prevalence of refractory hypertension was 3.6% among participants with resistant hypertension (n=2144) and 41.7% among participants on ≥5 antihypertensive drug classes. Among all participants with hypertension, black race, male sex, living in the stroke belt or buckle, higher body mass index, lower heart rate, reduced estimated glomerular filtration rate, albuminuria, diabetes mellitus, and history of stroke and coronary heart disease were associated with refractory hypertension. Compared with resistant hypertension, prevalence ratios for refractory hypertension were increased for blacks (3.00; 95% confidence interval, 1.68-5.37) and those with albuminuria (2.22; 95% confidence interval, 1.40-3.52) and diabetes mellitus (2.09; 95% confidence interval, 1.32-3.31). The median 10-year Framingham risk for coronary heart disease and stroke was higher among participants with refractory hypertension when compared with those with either comparator group. These data indicate that although resistant hypertension is relatively common among treated patients with hypertension, true antihypertensive treatment failure is rare.

Entities:  

Keywords:  diabetes mellitus, type 2; hypertension; risk factors; therapeutics

Mesh:

Substances:

Year:  2013        PMID: 24324035      PMCID: PMC4141646          DOI: 10.1161/HYPERTENSIONAHA.113.02026

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  24 in total

1.  Incidence and prognosis of resistant hypertension in hypertensive patients.

Authors:  Stacie L Daugherty; J David Powers; David J Magid; Heather M Tavel; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Joe V Selby; P Michael Ho
Journal:  Circulation       Date:  2012-02-29       Impact factor: 29.690

Review 2.  What is the prevalence of resistant hypertension in the United States?

Authors:  Dustin R Roberie; William J Elliott
Journal:  Curr Opin Cardiol       Date:  2012-07       Impact factor: 2.161

3.  Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk.

Authors:  Ajay K Gupta; Efthimia G Nasothimiou; Choon L Chang; Peter S Sever; Bjorn Dahlöf; Neil R Poulter
Journal:  J Hypertens       Date:  2011-10       Impact factor: 4.844

4.  Management of hypertension: summary of NICE guidance.

Authors:  Taryn Krause; Kate Lovibond; Mark Caulfield; Terry McCormack; Bryan Williams
Journal:  BMJ       Date:  2011-08-25

5.  Resistant hypertension? Assessment of adherence by toxicological urine analysis.

Authors:  Oliver Jung; Janis L Gechter; Cora Wunder; Alexander Paulke; Christine Bartel; Helmut Geiger; Stefan W Toennes
Journal:  J Hypertens       Date:  2013-04       Impact factor: 4.844

6.  Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.

Authors:  Alejandro de la Sierra; Julián Segura; José R Banegas; Manuel Gorostidi; Juan J de la Cruz; Pedro Armario; Anna Oliveras; Luis M Ruilope
Journal:  Hypertension       Date:  2011-03-28       Impact factor: 10.190

7.  Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008.

Authors:  Brent M Egan; Yumin Zhao; R Neal Axon; Walter A Brzezinski; Keith C Ferdinand
Journal:  Circulation       Date:  2011-08-08       Impact factor: 29.690

8.  Prevalence of resistant hypertension in the United States, 2003-2008.

Authors:  Stephen D Persell
Journal:  Hypertension       Date:  2011-04-18       Impact factor: 10.190

9.  Multiple imputation using chained equations: Issues and guidance for practice.

Authors:  Ian R White; Patrick Royston; Angela M Wood
Journal:  Stat Med       Date:  2010-11-30       Impact factor: 2.373

10.  Refractory hypertension: definition, prevalence, and patient characteristics.

Authors:  Maria Czarina Acelajado; Roberto Pisoni; Tanja Dudenbostel; Louis J Dell'Italia; Falynn Cartmill; Bin Zhang; Stacey S Cofield; Suzanne Oparil; David A Calhoun
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-11-15       Impact factor: 3.738

View more
  59 in total

1.  Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg.

Authors:  Gabriel S Tajeu; John N Booth; Lisandro D Colantonio; Rebecca F Gottesman; George Howard; Daniel T Lackland; Emily C O'Brien; Suzanne Oparil; Joseph Ravenell; Monika M Safford; Samantha R Seals; Daichi Shimbo; Steven Shea; Tanya M Spruill; Rikki M Tanner; Paul Muntner
Journal:  Circulation       Date:  2017-06-20       Impact factor: 29.690

2.  Racial differences in hypertension: implications for high blood pressure management.

Authors:  Daniel T Lackland
Journal:  Am J Med Sci       Date:  2014-08       Impact factor: 2.378

Review 3.  Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Hemal Bhatt; Monika Safford; Stephen Glasser
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

Review 4.  [Baroreflex activation therapy : Indication and evidence in resistant hypertension and heart failure].

Authors:  M Wallbach; M J Koziolek; R Wachter
Journal:  Internist (Berl)       Date:  2018-10       Impact factor: 0.743

Review 5.  Resistant Hypertension: An Update of Experimental and Clinical Findings.

Authors:  Anping Cai; David A Calhoun
Journal:  Hypertension       Date:  2017-05-15       Impact factor: 10.190

6.  Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure.

Authors:  Mohammed Siddiqui; Tanja Dudenbostel; David A Calhoun
Journal:  Can J Cardiol       Date:  2015-07-08       Impact factor: 5.223

7.  Hypertension: is the sham procedure 'toxic' for renal denervation?

Authors:  Costas Tsioufis
Journal:  Nat Rev Nephrol       Date:  2014-03-04       Impact factor: 28.314

Review 8.  African Americans, hypertension and the renin angiotensin system.

Authors:  Sandra F Williams; Susanne B Nicholas; Nosratola D Vaziri; Keith C Norris
Journal:  World J Cardiol       Date:  2014-09-26

9.  Resistant hypertension: do all definitions describe the same patients?

Authors:  L Boswell; J Pascual; A Oliveras
Journal:  J Hum Hypertens       Date:  2015-01-15       Impact factor: 3.012

10.  Selective Deletion of the Brain-Specific Isoform of Renin Causes Neurogenic Hypertension.

Authors:  Keisuke Shinohara; Xuebo Liu; Donald A Morgan; Deborah R Davis; Maria Luisa S Sequeira-Lopez; Martin D Cassell; Justin L Grobe; Kamal Rahmouni; Curt D Sigmund
Journal:  Hypertension       Date:  2016-10-17       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.